

|   |   |    |   |                          |                       |
|---|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <i>Complete if Known</i> |                       |
|   |   |    |   | Application Number       | 10/541,195            |
|   |   |    |   | Filing Date              | June 30, 2005         |
|   |   |    |   | First Named Inventor     | Patricia SALVATI      |
|   |   |    |   | Group Art Unit           | 1617                  |
|   |   |    |   | Examiner Name            | Sahar JAVANMARD       |
|   |   |    |   | Confirmation No.         | 7746                  |
| Sheet   | 1 | of | 7 | Attorney Docket No.      | 373987-004US (396982) |

| U.S. PUBLISHED DOCUMENTS |                          |                           |                            |  |  |
|--------------------------|--------------------------|---------------------------|----------------------------|--|--|
| Examiner<br>Initials*    | Cite<br>No. <sup>1</sup> | U.S. Publication Document |                            | Name of Patentee or Applicant<br>of Cited Document | Date of Publication of<br>Cited Document<br>MM-DD-YYYY |
|                          |                          | Number                    | Kind<br>Code (if<br>known) |  |  |
|                          | A1                       | US-3,549,690              |                            | Leigh et al.                                       | 12-22 -1970  |
|                          | A2                       | US-3,576,864              |                            | Nagarajan  | 04-27-1971   |
|                          | A3                       | US-3,658,967              |                            | Leigh et al.                                       | 04-25-1972   |
|                          | A4                       | US-4,049,663              |                            | Harper et al.                                      | 09-20-1977   |
|                          | A5                       | US-4,267,354              |                            | Krapcho et al.                                     | 05-12-1981   |
|                          | A6                       | US-4,311,853              |                            | Cree et al.  | 01-19-1982   |
|                          | A7                       | US-4,513,009              |                            | Roques et al.                                      | 04-23-1985   |
|                          | A8                       | US-4,631,287              |                            | Chakraborty et al.                                 | 12-23-1986   |
|                          | A9                       | US-4,639,468              |                            | Roncucci et al.                                    | 01-27-1987   |
|                          | A10                      | US-4,725,608              |                            | Nakaguchi et al.                                   | 02-16-1988   |
|                          | A11                      | US-4,725,619              |                            | Chakraborty et al.                                 | 02-16-1988   |
|                          | A12                      | US-4,839,369              |                            | Youssefyeh et al.                                  | 06-13-1989   |
|                          | A13                      | US- 4,927,835             |                            | Kise et al.  | 05-22-1990   |
|                          | A14                      | US-4,927,836              |                            | Holloway et al.                                    | 05-22-1990   |
|                          | A15                      | US-5,236,957              |                            | Dostert et al.                                     | 08-17-1993   |
|                          | A16                      | US-5,391,577              |                            | Dostert et al.                                     | 02-21-1995   |
|                          | A17                      | US-5,446,066              |                            | Varasi et al.                                      | 08-29 -1995  |
|                          | A18                      | US-5,449,692              |                            | Varasi et al.                                      | 09-12-1995   |
|                          | A19                      | US-5,475,007              |                            | Cai et al.   | 12-12-1995   |
|                          | A20                      | US-5,482,964              |                            | Hays   | 01-09-1996   |
|                          | A21                      | US-5,498,610              |                            | Chenard  | 03-12-1996   |
|                          | A22                      | US-5,502,079              |                            | Dostert et al.                                     | 03-16-1996   |

|                       |                   |                 |            |
|-----------------------|-------------------|-----------------|------------|
| Examiner<br>Signature | /Sahar Javanmard/ | Date Considered | 09/11/2008 |
|-----------------------|-------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

|   |   |    |   |                          |                       |
|---|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <i>Complete if Known</i> |                       |
|   |   |    |   | Application Number       | 10/541,195            |
|   |   |    |   | Filing Date              | June 30, 2005         |
|   |   |    |   | First Named Inventor     | Patricia SALVATI      |
|   |   |    |   | Group Art Unit           | 1617                  |
|   |   |    |   | Examiner Name            | Sahar JAVANMARD       |
|   |   |    |   | Confirmation No.         | 7746                  |
| Sheet   | 2 | of | 7 | Attorney Docket No.      | 373987-004US (396982) |

|  |     |                 |  |                  |            |
|--|-----|-----------------|--|------------------|------------|
|  | A23 | US-5,670,546    |  | Park et al.      | 09-23-1997 |
|  | A24 | US-5,688,830    |  | Berger et al.    | 11-18-1997 |
|  | A25 | US-5,723,489    |  | Sher et al.      | 03-03-1998 |
|  | A26 | US-5,741,818    |  | Dimmock          | 04-21-1998 |
|  | A27 | US-5,849,737    |  | Chaplan et al.   | 12-15-1998 |
|  | A28 | US-5,945,454    |  | Peverello et al. | 08-31-1999 |
|  | A29 | US-6,281,211    |  | Cai et al.       | 08-28-2001 |
|  | A30 | US-6,303,819    |  | Peverello et al. | 10-16-2001 |
|  | A31 | US-6,479,484    |  | Lan et al.       | 11-12-2002 |
|  | A32 | US-6,500,825    |  | Lan et al.       | 12-31-2002 |
|  | A33 | US-7,091,210    |  | Lan et al.       | 08-15-2006 |
|  | A34 | US-RE40,259     |  | Pevarello et al. | 04-22-2008 |
|  | A35 | US-2004/0248978 |  | Salvati          | 12-09-2004 |
|  | A36 | US-2007/0093495 |  | Ruggero et al.   | 04-26-2007 |
|  | A37 | US-2007/0203182 |  | Besana et al.    | 08-30-2007 |
|  | A38 | US-2008/096965  |  | Barbanhti et al. | 04-28-2008 |

| FOREIGN PATENT DOCUMENTS |                          |                         |           |                               |   |  |                          |    |
|--------------------------|--------------------------|-------------------------|-----------|-------------------------------|---|--|--------------------------|----|
| Examiner<br>Initials*    | Cite<br>No. <sup>1</sup> | Foreign Patent Document |           |                               | Date of<br>Publication of<br>Cited Document<br>MM-DD-<br>YYYY | Name of Patentee or Applicant<br>of Cited Document | Translation <sup>2</sup> |    |
|                          |                          | Office                  | Number    | Kind<br>Code<br>(if<br>known) |   |  | Yes                      | No |
|                          | B1                       | EP                      | 0200101   | A2                            | 12-10-1996  | USV Pharmaceutical Corp.                           |                          |    |
|                          | B2                       | EP                      | 0415143   | A1                            | 03-06-1991  | Warner-Lambert Co.                                 |                          |    |
|                          | B3                       | EP                      | 0 525 360 | A2                            | 02-03-1993  | Korea Research Institute of<br>Chemical Technology |                          |    |
|                          | B4                       | GB                      | 1140748   |                               | 01-22-1969  | Imperial Chemical Industries,<br>Ltd               |                          |    |
| Examiner<br>Signature    | /Sahar Javanmard/        |                         |           |                               |   | Date Considered                                    | 09/11/2008               |    |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

|   |   |    |   |                          |                       |
|---|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <i>Complete if Known</i> |                       |
|   |   |    |   | Application Number       | 10/541,195            |
|   |   |    |   | Filing Date              | June 30, 2005         |
|   |   |    |   | First Named Inventor     | Patricia SALVATI      |
|   |   |    |   | Group Art Unit           | 1617                  |
|   |   |    |   | Examiner Name            | Sahar JAVANMARD       |
|   |   |    |   | Confirmation No.         | 7746                  |
| Sheet   | 3 | of | 7 | Attorney Docket No.      | 373987-004US (396982) |

|  |     |    |          |   |            |                                     |  |  |
|--|-----|----|----------|---|------------|-------------------------------------|--|--|
|  | B5  | GB | 2059963  | A | 04-29-1981 | A.H. Robins Co., Inc.               |  |  |
|  | B6  | WO | 90/14334 |   | 11-29-1990 | Farmitalia Carlo Erba S.R.L.        |  |  |
|  | B7  | WO | 94/22808 |   | 10-13-1994 | Pharmacia/Farmitalia Carlo Erba SRL |  |  |
|  | B8  | WO | 94/22809 |   | 10-13-1994 | Pharmacia/Farmitalia Carlo Erba     |  |  |
|  | B9  | WO | 96/40628 |   | 12-19-1996 | The University of Saskatchewan      |  |  |
|  | B10 | WO | 97/05102 |   | 02-13-1997 | Pharmacia & Upjohn S.p.A.           |  |  |
|  | B11 | WO | 97/05111 |   | 02-13-1997 | Pharmacia & Upjohn S.p.A.           |  |  |
|  | B12 | WO | 98/19998 |   | 05-14-1998 | Novartis AG                         |  |  |
|  | B13 | WO | 98/25594 |   | 06-19-1998 | SmithKline Beecham PLC              |  |  |
|  | B14 | WO | 98/43964 |   | 10-08-1998 | Pharmacia & Upjohn S.p.A.           |  |  |
|  | B15 | WO | 98/47869 |   | 10-29-1998 | CoCensys, Inc.                      |  |  |
|  | B16 | WO | 99/26614 |   | 06-03-1999 | CoCensys, Inc.                      |  |  |
|  | B17 | WO | 99/35123 |   | 07-15-1999 | Newron Pharmaceuticals SpA          |  |  |
|  | B18 | WO | 99/35125 |   | 07-15-1999 | Newron Pharmaceuticals SpA          |  |  |
|  | B19 | WO | 99/39712 |   | 08-12-1999 | CoCensys, Inc.                      |  |  |
|  | B20 | WO | 00/61188 |   | 10-19-2000 | CoCensys, Inc.                      |  |  |

| OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS |                       |   |                          |    |  |
|---|-----------------------|---|--------------------------|----|--|
| Examiner Initials*                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | Translation <sup>2</sup> |    |  |
|   |                       |   | Yes                      | No |  |
|   | C1                    | Anonymous, "Cambridge NeuroScience's grant for channel blockers," <i>SCRIP World Pharmaceutical News</i> 1870:8 (1993)  |                          |    |  |
|   | C2                    | Anonymous, "Neurogen Licenses National Institutes of Health (NIH) anticonvulsants," <i>SCRIP World Pharmaceutical News</i> 1773:14 (1992)   |                          |    |  |
|   | C3                    | AWOUTERS (ed.), <i>Proceedings, XIVth International Symposium on Medicinal Chemistry</i> , Maastricht, The Netherlands, 8 - 12 September 1996, Elsevier Science B.V. (Amsterdam), (cover, front matter, table of contents, index of authors, subject index, Stanford University Libraries date stamp). Copyright 1997; date stamped 24 August 1998, Swain Library, Stanford University. |                          |    |  |
|   | C4                    | Bensimon, G., et al., "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis," <i>New Engl. J. Med.</i> 330:585-591 (1994)  |                          |    |  |

|                    |                   |                 |            |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Sahar Javanmard/ | Date Considered | 09/11/2008 |
|--------------------|-------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

|   |   |    |   |                          |                       |
|---|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <i>Complete if Known</i> |                       |
|   |   |    |   | Application Number       | 10/541,195            |
|   |   |    |   | Filing Date              | June 30, 2005         |
|   |   |    |   | First Named Inventor     | Patricia SALVATI      |
|   |   |    |   | Group Art Unit           | 1617                  |
|   |   |    |   | Examiner Name            | Sahar JAVANMARD       |
|   |   |    |   | Confirmation No.         | 7746                  |
| Sheet   | 4 | of | 7 | Attorney Docket No.      | 373987-004US (396982) |

|     |   |  |  |
|-----|---|--|--|
| C5  | Brown, C.M., <i>et al.</i> , "Neuroprotective properties of Lofarizine compared with those of other agents in a mouse model of focal cerebral ischaemia," <i>British J. Pharmacol.</i> 115:1425-1432 (1995)                       |  |  |
| C6  | Catterall, W.A., "Common modes of drug action on Na <sup>+</sup> channels: Local anesthetics, antiarrhythmics and anticonvulsants," <i>Trends Pharmacol. Sci.</i> 8:57-65 (1987)  |  |  |
| C7  | Catterall, W.A., "Neurotoxins that Act on Voltage-Sensitive Sodium Channels in Excitable Membranes," <i>Ann. Rev. Pharmacol. Toxicol.</i> 20:15-43 (1980)   |  |  |
| C8  | Catterall, W.A., "Structure and Function of Voltage-Sensitive Ion Channels," <i>Science</i> 242:50-61 (1988)  |  |  |
| C9  | Complaint, Civil Action No. 1:07-cv-00487 (March 12, 2007)  |  |  |
| C10 | Denicoff, K.D., <i>et al.</i> , "Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey," <i>J. Clin. Psychiatry</i> 55:70-76 (1994)  |  |  |
| C11 | Decision, Preliminary Motions, Bd.R. 125, interference no. 105,394 (2007)   |  |  |
| C12 | Dimmock, J.R., <i>et al.</i> , "(Aryloxy)aryl Semicarbazones and Related Compounds: A Novel Class of Anticonvulsant Agents Possessing High Activity in the Maximal Electroshock Screen," <i>J. Med. Chem.</i> 39:3984-3997 (1996) |  |  |
| C13 | Dostert <i>et al.</i> , "New anticonvulsants with selective MAO-B inhibitory activity," <i>European Neuropsychopharmacology</i> , 1(3):317-319 (September 1991)   |  |  |
| C14 | ELRIFI <i>et al.</i> , "Request for <i>ex parte</i> reexamination of U.S. patent no. 6,479,484 B1," filed July 2, 2003 on behalf of Newron Pharmaceuticals, SpA   |  |  |
| C15 | FARIELLO <i>et al.</i> , "Preclinical evaluation of PNU-151774E as a novel anticonvulsant," <i>J. Pharmacol. Exp. Ther.</i> 285(2):397-403 (May 1998)   |  |  |
| C16 | Faravelli L. <i>et al.</i> , "NW 1029 is a novel na <sup>+</sup> channel blocker, with analgesic activity in animal models." Abstract, Annual Meeting, Society for Neuroscience 2000; 26 (1):1218                                 |  |  |
| C17 | Fields, "Peripheral neuropathic pain: an approach to management," in PD Wall and R Melack (eds.), <i>Textbook of Pain</i> , 3 <sup>rd</sup> ed., Churchill Livingstone, pp. 991-996 (1994)  |  |  |
| C18 | (First) Declaration of Robert A. McArthur, Pevarello Exhibit 2036, interference 105,394 (2006)  |  |  |
| C19 | First Declaration of Stephen G. Waxman, M.D., Ph.D., PX 2003, interference no. 105,394 (2006)   |  |  |
| C20 | Galer BS, "Neuropathic pain of peripheral origin: advances in pharmacologic treatment," <i>Neurol.</i> 45:S17-S25, 1995   |  |  |
| C21 | Guieu <i>et al.</i> , "Central analgesic effect of valproate in patients with epilepsy," <i>Seizure</i> 2:147-150 (1993)  |  |  |

|                    |                   |                 |            |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Sahar Javanmard/ | Date Considered | 09/11/2008 |
|--------------------|-------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

|   |          |           |          |                             |                              |
|---|----------|-----------|----------|-----------------------------|------------------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |          |           |          | <b>Complete if Known</b>    |                              |
|   |          |           |          | <b>Application Number</b>   | <b>10/541,195</b>            |
|   |          |           |          | <b>Filing Date</b>          | <b>June 30, 2005</b>         |
|   |          |           |          | <b>First Named Inventor</b> | <b>Patricia SALVATI</b>      |
|   |          |           |          | <b>Group Art Unit</b>       | <b>1617</b>                  |
|   |          |           |          | <b>Examiner Name</b>        | <b>Sahar JAVANMARD</b>       |
|   |          |           |          | <b>Confirmation No.</b>     | <b>7746</b>                  |
| <b>Sheet</b>  | <b>5</b> | <b>of</b> | <b>7</b> | <b>Attorney Docket No.</b>  | <b>373987-004US (396982)</b> |

|     |   |  |  |
|-----|---|--|--|
| C22 | Graham, S.H., <i>et al.</i> , "Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion," <i>J. Pharmacol. Exp. Ther.</i> 269:854-859 (1994)            |  |  |
| C23 | Hammer <i>et al.</i> , "Effect of Riluzole on acute pain and hyperalgesia in humans," <i>Brit. J. Anaesthesia</i> 82(5):718-22 (1999)   |  |  |
| C24 | International Search Report for PCT/EP03/12889 dated Feb. 3, 2004.  |  |  |
| C25 | Judgment, Preliminary Motions, Bd.R. 127, interference no. 105,394 (2007)   |  |  |
| C26 | Kingery, "A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes," <i>Pain</i> 73:123-139 (1997)   |  |  |
| C27 | Lunardi <i>et al.</i> , "Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia," <i>Neurology</i> 48(6):1714-1717 (1997)  |  |  |
| C28 | Magnus L., "Nonepileptic uses of gabapentin experience," <i>Epilepsia</i> , 1999; 40 (Suppl. 6) S66-72; discussion 873-874  |  |  |
| C29 | Mathew, Ninan T., "Pathophysiology, epidemiology and impact of Migraine" <i>Clinical Cornerstone</i> , vol. 4, no. 3, 2001, pages 1-17  |  |  |
| C30 | May et al., "The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation," <i>J. Cereb. Blood flow Metab.</i> , vol. 9, 1999, pages 115-127 |  |  |
| C31 | McQuay <i>et al.</i> , "Anticonvulsant drugs for management of pain: a systematic review," <i>BMJ</i> 311:1047-1052 (21 October 1995)   |  |  |
| C32 | Memorandum Opinion and Order, interference no. 105,394 (2007)   |  |  |
| C33 | Nakamura-Craig <i>et al.</i> , "Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE <sub>2</sub> and in the chronic hyperalgesia in rats with streptozocin-induced diabetes," <i>Pain</i> 63:33-37 (1995)          |  |  |
| C34 | Notice Of Dismissal With Prejudice, Civil Action No. 1:07-cv-00487 (July 25, 2007)  |  |  |
| C35 | Official action, counterpart Brazilian application (to RE40,259) no. PI 9814548-7 (translation)   |  |  |
| C36 | Peitl B. <i>et al.</i> , "Capsaicin-insensitive sensory-efferent meningeal vasodilatation evoked by electrical stimulation of trigeminal nerve fibres in the rat," <i>British Journal of Pharmacology</i> (1999) 127, 457-467.            |  |  |
| C37 | Pevarello <i>et al.</i> , "Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanide Derivatives", <i>J. Med. Chem.</i> 41:579-590 (1998)  |  |  |
| C38 | PEVARELLO <i>et al.</i> , "Stereoselectivity, sigma binding and sodium channel blocking activity of 2-amino propanamide anticonvulsants." (3 pages) (September 12, 1996).   |  |  |
| C39 | Puig et al., "Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity," <i>Pain</i> 64:345-355 (1995)  |  |  |

|                           |                   |                        |            |
|---------------------------|-------------------|------------------------|------------|
| <b>Examiner Signature</b> | /Sahar Javanmard/ | <b>Date Considered</b> | 09/11/2008 |
|---------------------------|-------------------|------------------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

|   |   |    |   |                          |                       |
|---|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <i>Complete if Known</i> |                       |
|   |   |    |   | Application Number       | 10/541,195            |
|   |   |    |   | Filing Date              | June 30, 2005         |
|   |   |    |   | First Named Inventor     | Patricia SALVATI      |
|   |   |    |   | Group Art Unit           | 1617                  |
|   |   |    |   | Examiner Name            | Sahar JAVANMARD       |
|   |   |    |   | Confirmation No.         | 7746                  |
| Sheet   | 6 | of | 7 | Attorney Docket No.      | 373987-004US (396982) |

|     |   |  |  |
|-----|---|--|--|
| C40 | Reuter U. <i>et al.</i> , "Experimental models of migraine", <i>Functional neurology</i> (15) Suppl. 3 9-18, 2000   |  |  |
| C41 | SALVATI <i>et al.</i> , "Anticonvulsant profile of FCE26743A (PNU-151774), a novel 2-aminopropionamide derivative. Society for Neuroscience. Washington. Nov 15 - 21, 1996." (4 pages) (November 21, 1996, date solely for purpose of initial consideration)                      |  |  |
| C42 | Saxena <i>et al.</i> : "Pharmacology of antimigraine drugs," <i>Journal of Neurology</i> , 1991, pages S28-S35  |  |  |
| C43 | Shibata <i>et al.</i> , "Modified formalin test: characteristic biphasic pain response," <i>Pain</i> 38:347-352 (1989)  |  |  |
| C44 | Steiner <i>et al.</i> : "Lamotrigine versus placebo in the prophylaxis of migraine with and without aura" <i>Cephalgia</i> , vol. 17, 1997, pages 109-112   |  |  |
| C45 | Stys, P.K., <i>et al.</i> , "Ionic Mechanism of Anoxic Injury in Mammalian CNS White Matter: Role of Na <sub>v</sub> Channels and Na <sup>+</sup> -Ca <sup>2+</sup> Exchanger," <i>J. Neurosci.</i> 12:430-439 (1992)   |  |  |
| C46 | Supplemental data, Vieth <i>et al.</i> , "Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs," <i>J. Med. Chem.</i> 47:224-232 (2004) (downloaded August 20, 2007 from <a href="http://pubs.acs.org">http://pubs.acs.org</a> ) (excerpted fields) |  |  |
| C47 | Tanelian <i>et al.</i> , "Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine," <i>Anesthesiol.</i> 74(5):949-951 (1991)   |  |  |
| C48 | Tanelian <i>et al.</i> , "Sodium channel-blocking agents: their use in neuropathic pain conditions," <i>Pain Forum</i> 4(2):75-80 (1995)  |  |  |
| C49 | Taylor, C.P. and Meldrum, B.S., "Na <sup>+</sup> channels as targets for neuroprotective drugs," <i>Trends Pharmacol. Sci.</i> 16:309-316 (1995)  |  |  |
| C50 | Tjolsen <i>et al.</i> , "The formalin test: an evaluation of the method," <i>Pain</i> 51:5-17 (1992)  |  |  |
| C51 | Vaghi <i>et al.</i> , "Neuroprotective effect of PNU-151774E, a new anticonvulsant compound, in the model of global ischaemia in gerbils." (5 pages) (October 30, 1997, date solely for purpose of initial consideration)   |  |  |
| C52 | Varasi <i>et al.</i> , "Synthesis and anticonvulsant activity of new benzyloxybenzylacetamide derivatives," from <i>Abstracts, XII<sup>th</sup> International Symposium on Medicinal Chemistry</i> , Basel, Switzerland, September 13-17, 1992 (2 pages) (1992)                   |  |  |
| C53 | Varasi <i>et al.</i> , "Synthesis and anticonvulsant activity of new benzyloxybenzylacetamide derivatives" (2 pages) (1992)   |  |  |
| C54 | Vieth <i>et al.</i> , "Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs," <i>J. Med. Chem.</i> 47:224-232 (2004)  |  |  |
| C55 | Webber, "Observations under article 115 EPC", filed November 19, 2002 in EP 98958114.5 (EP 1032377) on behalf of Newron Pharmaceuticals, SpA  |  |  |

|                    |                   |                 |            |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Sahar Javanmard/ | Date Considered | 09/11/2008 |
|--------------------|-------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

|   |   |    |   |                          |                       |
|---|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <i>Complete if Known</i> |                       |
|   |   |    |   | Application Number       | 10/541,195            |
|   |   |    |   | Filing Date              | June 30, 2005         |
|   |   |    |   | First Named Inventor     | Patricia SALVATI      |
|   |   |    |   | Group Art Unit           | 1617                  |
|   |   |    |   | Examiner Name            | Sahar JAVANMARD       |
|   |   |    |   | Confirmation No.         | 7746                  |
| Sheet   | 7 | of | 7 | Attorney Docket No.      | 373987-004US (396982) |

|  |            |  |  |  |
|--|------------|--|--|--|
|  | <b>C56</b> | Wenzel <i>et al.</i> : "Migraine headache misconceptions: barriers to effective care" <i>Pharmacotherapy</i> , vol. 24, no. 5, 2004, pages 638-648   |  |  |
|  | <b>C57</b> | Wilton, "Tegretol in the treatment of diabetic neuropathy," <i>S. Afr. Med. J.</i> 48(20):869-872 (1974)   |  |  |
|  | <b>C58</b> | Woolf <i>et al.</i> , "The systemic administration of local anaesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord," <i>Pain</i> 23(4):361-374 (1985) |  |  |

14359744.1.BUSINESS

|                    |                   |                 |            |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Sahar Javanmard/ | Date Considered | 09/11/2008 |
|--------------------|-------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./